Stroke Prevention in Sickle Cell Anemia (STOP 2)


Phase 3 Results


The trial had enrolled 79 patients when it was stopped two years early. Of the 41 patients in whom transfusions were discontinued, 14 (34%) reverted to a high risk of stroke and 2 patients had suffered a stroke. There were no events nor increases in stroke risk among the patients who continued transfusions.